How immunotherapy can enhance the response to other modalities and improve outcome and quality of life

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Liu, W M ^a   Meyer, B ^a   Dalgleish, Angus Dalgleish ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy; Combinations; DC vaccines; Immunotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GAMMA INTERFERON; GEMCITABINE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 4; LENALIDOMIDE; PACLITAXEL; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; TUMOR ANTIGEN; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL HETEROGENEITY; CELL INTERACTION; CELLULAR IMMUNITY; CONFERENCE PAPER; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPOTENTIATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MYELOMA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; QUALITY OF LIFE;

EID: 70350071770     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Liu WM. Enhancing the cytotoxic activity of novel targeted therapies - is there a role for a combinatorial approach? Curr Clin Pharmacol 2008; 3: 108-117.
3. Rasmussen L, Arvin A. Chemotherapy-induced immunosuppression. Environ Health Perspect 1982; 43: 21-25.
4. Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004; 23: 981-990. (Pubitemid 38250944)
5. Brock CS, Newlands ES, Wedge SR et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998; 58: 4363-4367. (Pubitemid 28450038)
6. Su YB, Sohn S, Krown SE et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22: 610-616. (Pubitemid 41095063)
7. Pagani E, Pepponi R, Fuggetta MP et al. DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system. J Chemother 2003; 15: 173-183. (Pubitemid 36609755)
8. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373: 1033-1040.
9. Meyer B, Liu WM, Dalgleish A, Galustian C. The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy. Curr Signal Transd 2009; 4: 122-129.
10. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008; 28: 109-126.
11. Schiavoni G, Mattel F, Di Pucchio T et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95: 2024-2030. (Pubitemid 30151641)
12. Berd D, Maguire HC Jr, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44: 5439-5443. (Pubitemid 15204525)
13. Livingston PO, Cunningham-Rundles S, Marfleet G et al. Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod 1987; 6: 392-403. (Pubitemid 17112189)
14. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008; 333: 167-179.
15. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002; 62: 2353-2358.
16. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005; 54: 915-925. (Pubitemid 40991334)
17. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-6721. (Pubitemid 41339014)
18. Bronte V, Apolloni E, Cabrelle A et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96: 3838-3846.
19. Huang Y, Chen X, Dikov MM et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110: 624-631.
20. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
21. Almand B, Resser JR, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6: 1755-1766. (Pubitemid 30305068)
22. Boissel N, Rousselot P, Raffoux E et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004; 18: 1656-1661. (Pubitemid 39386344)
23. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14: 6674-6682.
24. van Cruijsen H, van der Veldt AA, Vroling L et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008; 14: 5884-5892.
25. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157.
26. Ozao-Choy J, Ma G, Kao J et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-2522.
27. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524. (Pubitemid 43854967)
28. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648. (Pubitemid 46348738)
29. Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007; 177: 2136-2140. (Pubitemid 46726410)
30. Audia S, Nicolas A, Cathelin D et al. Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes. Clin Exp Immunol 2007; 150: 523-530. (Pubitemid 350098743)
31. O'Mahony D, Morris JC, Quinn C et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007; 13: 958-964. (Pubitemid 46340373)
32. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135-142. (Pubitemid 34141443)
33. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006; 176: 6434-6442. (Pubitemid 43787825)
34. Marriott JB, Muller G, Stirling D, Dalgleish AG. Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 2001; 1: 675-682.
35. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-322. (Pubitemid 38525287)
36. Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 2009; 10: 125-133.
37. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996; 8: 271-280.
38. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807-839.
39. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-3290. (Pubitemid 46763021)
40. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310.
41. Liu WM, Smith P, Fowler D, Dalgleish AG. Chemotherapy increases HLA-ABC expression on tumour cells and promotes allogeneic cytotoxic responses. Proceedings of ECCO15/ESMO34 2009; abstr 1.102.
42. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3: 1001-1010. (Pubitemid 39642363)
43. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005; 5: 397-405.
44. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 1999; 96: 5340-5342.
45. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol 2004; 5: 681-689.
46. de Vries IJ, Lesterhuis WJ, Scharenborg NM et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003 9: 5091-5100.
47. Jonuleit H, Kühn U, Müller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135-3142. (Pubitemid 28018007)
48. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-238. (Pubitemid 32524454)
49. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-1222. (Pubitemid 30826423)
50. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007; 156: 337-345.
51. Schmidt CS, Morrow WJ, Sheikh NA. Smart adjuvants. Expert Rev Vaccines 2007; 6: 391-400.
52. Tsuda N, Chang DZ, Mine T et al. Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. Cancer Res 2007; 67: 8378-8387. (Pubitemid 47395177)
53. Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003; 14: 461-466. (Pubitemid 36367426)
54. Neninger E, Verdecia BG, Crombet T et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced non small cell lung cancer. J Immunother 2009; 32: 92-99.
55. Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009; 21: 201-209.
56. Hirooka Y, Itoh A, Kawashima H et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas 2009; 38: e69-e74.
57. Bauer C, Bauernfeind F, Sterzik A et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 2007; 56: 1275-1282. (Pubitemid 47300430)